Affymetrix Microarrays Used to Study Tuberculosis and Malaria; AMB Features Two Interviews With Researchers From Imperial Colleg
February 15 2006 - 8:00AM
Business Wire
Affymetrix Microarray Bulletin (AMB) today published interviews
with researchers from the Scripps Research Institute and Imperial
College London who are using microarrays to understand the
pathogenesis of Malaria-causing Plasmodium falciparum and the
hypervirulent Beijing/W Tuberculosis strain. Headlines for Feb. 15,
2006 AMB Issue: -- Microarray Analysis Characterizes Function of
95% of Malaria-causing Plasmodium falciparum Genes, Three Times
More than Ever Before: The Scripps Institute's Elizabeth Winzeler
and the Sanger Institute's Celine Carret discuss recent advances in
malaria research made possible using whole-genome Plasmodium
microarrays -- Researchers Discover Large Genomic Deletions in
Hypervirulent Beijing/W Tuberculosis Strains: Imperial College
London's Anthony Tsolaki and McGill's Serge Mostowy discuss the
large genetic differences found among strains of Mycobacterium
tuberculosis To view the complete stories, please visit:
http://microarraybulletin.com/community Affymetrix Microarray
Bulletin (AMB) is a magazine published by Affymetrix, Inc.
(Nasdaq:AFFX) that highlights leading microarray research and
diagnostic developments around the world. AMB features interviews
by and for scientists, statisticians and software engineers -- one
expert interviewing another. Our goal is to create a forum where
this community can discuss research and share new resources and
information. For more information about AMB, please visit the
publication's website at www.microarraybulletin.com About
Affymetrix: Affymetrix scientists invented the world's first
high-density microarray in 1989 and began selling the first
commercial microarray in 1994. Since then, Affymetrix GeneChip(R)
technology has become the industry standard in molecular biology
research. Affymetrix technology is used by the world's top
pharmaceutical, diagnostic and biotechnology companies as well as
leading academic, government and not-for-profit research
institutes. More than 1,300 systems have been installed around the
world and nearly 4,000 peer-reviewed papers have been published
using the technology. Affymetrix' patented photolithographic
manufacturing process provides the most information capacity
available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between
genetics and health. Affymetrix is headquartered in Santa Clara,
Calif. with subsidiaries in Europe and Asia, as well as
manufacturing facilities in Sacramento, Calif. and Bedford, Mass.
The company has about 1,000 employees worldwide. For more
information about Affymetrix, please visit the company's website at
www.Affymetrix.com. NOTE: Affymetrix, the Affymetrix logo, and
GeneChip are registered trademarks owned or used by Affymetrix Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024